Discontinuation of {beta}-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial
Choi,K. H.,Kim,J.,Kang,D.,Doh,J.-H.,Kim,J.,Park,Y. H.,Ahn,S. G.,Kim,W.,Park,J. P.,Kim,S. M.,Cho,B.-R.,Nam,C.-W.,Cho,J. H.,Joo,S.-J.,Suh,J.,Jeong,J.-O.,Jang,W.,Yoon,C.-H.,Hwang,J.-Y.,Lim,S.-H.,Lee,S.-R.,Shin,E.-S.,Kim,B. J.,Yu,C. W.,Her,S.-H.,Kim,H. K.,Park,K. T.,Kim,J.,Park,T. K.,Lee,J.-M.,Cho,J.,Yang,J. H.,Song,Y. B.,Choi,S. H.,Gwon,H.-C.,Guallar,E.,Hahn,J.-Y.,for the SMART-DECISION investigators
DOI: https://doi.org/10.1136/bmjopen-2024-086971
IF: 3.006
2024-09-04
BMJ Open
Abstract:Introduction There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction. Methods and analysis The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing β-blocker therapy for ≥1 year after AMI. A total of 2540 patients will be randomised 1:1 to continuation of β-blocker therapy or not. Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol or other) and participating centre. The primary study endpoint is a composite of all-cause death, MI and hospitalisation for HF over a median follow-up period of 3.5 years (minimum, 2.5 years; maximum, 4.5 years). Adverse effects related to β-blocker therapy, the occurrence of atrial fibrillation, medical costs and Patient-reported Outcomes Measurement Information system-29 questionnaire responses will also be collected as secondary endpoints. Ethics and dissemination Ethics approval for this study was granted by the Institutional Review Board of Samsung Medical Center (no. 2020-10-176). Informed consent is obtained from every participant before randomisation. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Trial registration number ClinicalTrials.gov, NCT04769362.
medicine, general & internal